TRB-061
Atopic dermatitis (and other inflammatory diseases)
Phase 1Active
Key Facts
About TRexBio
TRexBio is a private, preclinical-to-clinical stage biotech leveraging human tissue biology to develop novel Treg-targeting therapeutics for immune-mediated diseases. The company's core asset is its Deep Biology Platform, which analyzes human tissue samples across health and disease states to map immune dysregulation and identify actionable targets. Its lead candidate, TRB-061, a TNFR2 agonist, is in clinical development for atopic dermatitis, with a broader pipeline aimed at dermatology and gastroenterology. The company is backed by a strong team and investor syndicate, positioning it to pursue durable, disease-modifying treatments in large inflammatory disease markets.
View full company profile